Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Antibody-Drug Therapeutic Conjugates: Potential of Antibody-Sirnas in Cancer Therapy Publisher Pubmed



Yarian F1, 2 ; Alibakhshi A1, 2 ; Eyvazi S1, 2 ; Arezumand R3 ; Ahangarzadeh S4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Medical Biotechnology and Molecular Science, North Khorasan University of Medical Science, Bojnurd, Iran
  4. 4. Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Cellular Physiology Published:2019


Abstract

Codelivery is a promising strategy of targeted delivery of cytotoxic drugs for eradicating tumor cells. This rapidly growing method of drug delivery uses a conjugate containing drug linked to a smart carrier. Both two parts usually have therapeutic properties on the tumor cells. Monoclonal antibodies and their derivatives, such as Fab, scFv, and bsAb due to targeting high potent have now been attractive candidates as drug targeting carrier systems. The success of some therapeutic agents like small interfering RNA (siRNA), a small noncoding RNAs, with having problems such as enzymatic degradation and rapid renal filtration need to an appropriate carrier. Therefore, the aim of this study is to review the recent enhancements in development of antibody drug conjugates (ADCs), especially antibody–siRNA conjugates (SRCs), its characterizations and mechanisms in innovative cancer therapy approaches. © 2019 Wiley Periodicals, Inc.
Related Docs
View other Related Docs
1. Adcs, As Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies, Current Drug Delivery (2020)
2. Antibody-Drug Conjugates: Possibilities and Challenges, Avicenna Journal of Medical Biotechnology (2019)
3. Targeting Sirna in Colorectal Cancer Therapy: Nanotechnology Comes Into View, Journal of Cellular Physiology (2019)
4. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
5. Maldi-Ms: A Rapid and Reliable Method for Drug-To-Antibody Ratio Determination of Antibody-Drug Conjugates, Iranian Biomedical Journal (2019)
6. Types of Rna Therapeutics, Progress in Molecular Biology and Translational Science (2024)
7. Sirna Delivery for Treatment of Degenerative Diseases, New Hopes and Challenges, Journal of Drug Delivery Science and Technology (2018)
8. Overview of Cd24 As a New Molecular Marker in Ovarian Cancer, Journal of Cellular Physiology (2019)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (7)
Amirhasan Zarnani (3)
Other Related Docs
9. Nanoparticle-Sirna: A Potential Strategy for Ovarian Cancer Therapy?, Nanomedicine (2019)
10. The Applications of Anti-Cd20 Antibodies to Treat Various B Cells Disorders, Biomedicine and Pharmacotherapy (2019)
11. Immune Therapy of Melanoma: Overview of Therapeutic Vaccines, Journal of Cellular Physiology (2019)
12. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
13. Data-Driven Discovery of Molecular Targets for Antibody-Drug Conjugates in Cancer Treatment, BioMed Research International (2021)
14. Increasing Angiogenesis Factors in Hypoxic Diabetic Wound Conditions by Sirna Delivery: Additive Effect of Lbl-Gold Nanocarriers and Desloratadine-Induced Lysosomal Escape, International Journal of Molecular Sciences (2021)
15. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)
16. Reinforcing the Primary Immunotherapy Modulators Against Acute Leukemia; Monoclonal Antibodies in Aml, Immunotherapy (2019)
17. Sirna Nanotherapeutics: A Promising Strategy for Anti-Hbv Therapy, IET Nanobiotechnology (2019)
18. Gene Therapy to Enhance Angiogenesis in Chronic Wounds, Molecular Therapy Nucleic Acids (2022)
19. Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates, Iranian Biomedical Journal (2017)
20. Bevacizumab Antibody Affinity Maturation to Improve Ovarian Cancer Immunotherapy: In Silico Approach, International Journal of Peptide Research and Therapeutics (2019)
21. Immunotherapy for Breast Cancer Treatment, Iranian Biomedical Journal (2021)
22. Novel Trastuzumab-Dm1 Conjugate: Synthesis and Bio-Evaluation, Journal of Cellular Physiology (2019)
23. Targeted Cancer Therapy Through Antibody Fragments-Decorated Nanomedicines, Journal of Controlled Release (2017)
24. Combination Therapy of Macromolecules and Small Molecules: Approaches, Advantages, and Limitations, Nanostructures for Cancer Therapy (2017)
25. Recent Progress in Immunotherapy of Breast Cancer Targeting the Human Epidermal Growth Factor Receptor 2 (Her2), Journal of Oncology Pharmacy Practice (2021)
26. Microrna-181 Serves As a Dual-Role Regulator in the Development of Human Cancers, Free Radical Biology and Medicine (2020)
27. Anti-Cancer Therapeutic Strategies Based on Hgf/Met, Epcam, and Tumor-Stromal Cross Talk, Cancer Cell International (2022)
28. Nano-Delivery System Targeting to Cancer Stem Cell Cluster of Differentiation Biomarkers, Journal of Controlled Release (2017)
29. Introduction on Treatment for Infectious Diseases and Immunological Disorders, Encyclopedia of Infection and Immunity (2022)
30. Current Trends in Targeted Therapy for Drug-Resistant Infections, Applied Microbiology and Biotechnology (2019)
31. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
32. Multicomponent Sirna/Mirna-Loaded Modified Mesoporous Silica Nanoparticles Targeted Bladder Cancer for a Highly Effective Combination Therapy, Frontiers in Bioengineering and Biotechnology (2022)
33. Programmable and Multi-Targeted Cars: A New Breakthrough in Cancer Car-T Cell Therapy, Clinical and Translational Oncology (2021)
34. Nonviral Sirna Delivery Systems for Pancreatic Cancer Therapy, Biotechnology and Bioengineering (2021)
35. An Update on Antiviral Antibody-Based Biopharmaceuticals, International Immunopharmacology (2020)
36. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
37. Biodegradable Nano-Polymers As Delivery Vehicles for Therapeutic Small Non-Coding Ribonucleic Acids, Journal of Controlled Release (2017)
38. Nano-Scale Delivery Systems for Sirna Delivery in Cancer Therapy: New Era of Gene Therapy Empowered by Nanotechnology, Environmental Research (2023)
39. T Cell Engineered With a Novel Nanobody-Based Chimeric Antigen Receptor Against Vegfr2 As a Candidate for Tumor Immunotherapy, IUBMB Life (2019)
40. Remote Controlling of Car-T Cells and Toxicity Management: Molecular Switches and Next Generation Cars, Translational Oncology (2021)
41. Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers, Frontiers in Immunology (2017)
42. Prospects for the Potential of Rna Interference in the Treatment of Autoimmune Diseases: Small Interfering Rnas in the Spotlight, Journal of Autoimmunity (2020)
43. The Use of Objective Oriented Project Planning Tools for Nanosafety and Health Concerns: A Case Study in Nanomedicine Research Project, European Journal of Nanomedicine (2016)
44. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review, Current Cancer Therapy Reviews (2024)
45. Licensed Monoclonal Antibodies and Associated Challenges, Human Antibodies (2015)
46. Targeting Macrophage-Mediated Tumor Cell Phagocytosis: An Overview of Phagocytosis Checkpoints Blockade, Nanomedicine Intervention, and Engineered Car-Macrophage Therapy, International Immunopharmacology (2022)